Trending Articles
-
The first clinical trial of the investigational drug enasidenib, which targets IDH2 mutations, suggests that it is safe and may improve survival in patients with relapsed or refractory acute myeloid leukemia. It induced responses in 40.3% of patients, yielding a median overall survival of 9.3 months.
-
Review
Accuracy of diagnostic tests read with and without clinical information: a systematic review.
Although it is common practice to read tests with clinical information, whether this improves or decreases the accuracy of test reading is uncertain. ⋯ At least for the tests examined, the common practice of reading diagnostic tests with clinical information seems justified. Future studies should be designed to investigate the best way of providing clinical information. These studies should also give an estimate of the accuracy of clinical information used, display ROC curves with identified data points, and include a wider range of diagnostic tests.
-
Clinical cardiology · May 2005
Comparative StudyPeripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial.
Patients with peripheral arterial disease (PAD) represent a high-risk patient subset in the setting of non-ST-segment elevation acute coronary syndromes (NSTE ACS). The efficacy and safety of early invasive management for such patients remains unclear. ⋯ Among patients with NSTE ACS and a history of PAD, early invasive management is well tolerated and accompanied by significant reductions in morbidity and mortality when compared with a more conservative, ischemia-driven approach.